PSUSA/00000749/202402
Submitted by Anonymous (not verified) on 16 October 2024 - 16:34
PSUSA/00000749/202402
Human medicines European public assessment report (EPAR): Vyepti, eptinezumab, Date of authorisation: 24/01/2022, Revision: 7, Status: Authorised
Submitted by Anonymous (not verified) on 16 October 2024 - 15:06
Human medicines European public assessment report (EPAR): Vyepti, eptinezumab, Date of authorisation: 24/01/2022, Revision: 7, Status: Authorised
Orphan designation: Enzastaurin hydrochloride Treatment of glioma, 27/05/2024 Withdrawn
Submitted by Anonymous (not verified) on 16 October 2024 - 14:42
Orphan designation: Enzastaurin hydrochloride Treatment of glioma, 27/05/2024 Withdrawn
Agenda - ACT EU multi-stakeholder platform annual meeting
Submitted by Anonymous (not verified) on 16 October 2024 - 14:23
Agenda - ACT EU multi-stakeholder platform annual meeting
Union procedure on the coordination of veterinary pharmacovigilance inspections
Submitted by Anonymous (not verified) on 16 October 2024 - 13:00
Union procedure on the coordination of veterinary pharmacovigilance inspections
Union procedure on the preparation, conduct and reporting of EU veterinary pharmacovigilance inspections
Submitted by Anonymous (not verified) on 16 October 2024 - 13:00
Union procedure on the preparation, conduct and reporting of EU veterinary pharmacovigilance inspections
Union procedure on the coordination of veterinary pharmacovigilance inspections
Submitted by Anonymous (not verified) on 16 October 2024 - 13:00
Union procedure on the coordination of veterinary pharmacovigilance inspections
Union procedure on the preparation, conduct and reporting of EU veterinary pharmacovigilance inspections
Submitted by Anonymous (not verified) on 16 October 2024 - 13:00
Union procedure on the preparation, conduct and reporting of EU veterinary pharmacovigilance inspections
Human medicines European public assessment report (EPAR): Reyataz, atazanavir sulfate, Date of authorisation: 01/03/2004, Revision: 57, Status: Authorised
Submitted by Anonymous (not verified) on 16 October 2024 - 12:06
Human medicines European public assessment report (EPAR): Reyataz, atazanavir sulfate, Date of authorisation: 01/03/2004, Revision: 57, Status: Authorised
Human medicines European public assessment report (EPAR): Mevlyq, eribulin, Date of authorisation: 09/02/2024, Revision: 1, Status: Authorised
Submitted by Anonymous (not verified) on 16 October 2024 - 11:28
Human medicines European public assessment report (EPAR): Mevlyq, eribulin, Date of authorisation: 09/02/2024, Revision: 1, Status: Authorised